Novavax’s president and CEO reviewed the company’s successes in 2025 and shared its growth strategy for 2026 and beyond at a ...

Enanta’s portfolio of RSV replication inhibitors with potential for first-in-disease and best-in-disease treatment.

The funding aims to encourage innovation in Europe amid concerns that innovation across the continent is lagging behind China ...

Jazz Pharmaceuticals has sold a priority review voucher (PRV) for $200m, suggesting the uptick in market prices for the ...

The ‘KojoX’ method of cloning facilities around the globe keeps the CDMO agile in an industry fractured by geopolitical ...

The company has made more than 50 deals for its proprietary technology as it looks forward to a potentially “transformative” ...

The FDA and EMA's joint guidance was created to ensure the pharmaceutical industry employs best practices when using AI in ...

To thrive beyond rare disease, cell and gene therapy developers must scale-up manufacturing and commercialisation.

Novo Nordisk is positioning itself as a long‑term leader across multiple obesity segments rather than relying on a single ...

Eli Lilly highlighted 2025 as the rollout year for obesity drugs, with Mounjaro at the forefront of its weight-loss portfolio ...

WuXi AppTec highlighted the strength of its integrated CRDMO model and growing exposure to late-stage and commercial assets ...

Wuxi Biologics highlighted their highly integrated and scaled platform, allowing for end-to-end research, development and manufacturing of complex biologics.